FDA Committee Votes To Back Eli Lilly’s Alzheimer’s Drug

The FDA will now take the committee’s advice into consideration as it decides whether to greenlight the drug.

An FDA committee voted to endorse Eli Lilly’s drug aimed at helping people with Alzheimer’s.

‘Donanemab’ is a monoclonal antibody designed to slow the progression of early symptomatic Alzheimer’s. It works by helping the body remove amyloid plaque build-ups in the brain that are a hallmark of the disease. The plaques are harmful deposits that can form as people age.

Removing the plaque seems to slow down the brain changes and after reviewing data from late-stage clinical research, the panel of independent advisers to the FDA have agreed that it is safe and effective.

The FDA will now take the committee’s advice into consideration as it decides whether to greenlight the drug.